Table 2 Clinical features and percentage of CD62L positive CD62LCD4+ T cells in 6 patients who discontinued the NTZ treatment
From: Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells
During NTZ infusion | After NTZ withdrawal | ||||||
|---|---|---|---|---|---|---|---|
JCV index | Number of infusion | CD62LCD4 (%) | Number of months | CD62LCD4 (%) | MRI | Relapse | |
Pt #1 | 3.498 | 40 | 5.65 | 5 | 49.07 | Neg | None |
Pt #2 | 2.488 | 16 | 16.34 | 3 | 56.48 | Neg | None |
Pt #3 | 2.696 | 20 | 35.44 | 4 | 32.21 | Pos | 1 |
Pt #4 | 2.034 | 71 | 44.50 | 3 | 42.32 | Neg | None |
Pt #5 | 1.366 | 66 | 15.83 | 4 | 56.59 | Neg | None |
Pt #6 | 2.304 | 32 | 41.18 | 3 | 27.78 | Neg | None |